Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
alnylam pharmaceuticals
3
×
boston blog main
boston top stories
3
×
clinical trials
life sciences
national blog main
3
×
national top stories
new york blog main
new york top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
biotech
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
fda
indiana blog main
indiana top stories
national
raleigh-durham blog main
raleigh-durham top stories
regeneron pharmaceuticals
rna interference
seattle blog main
seattle top stories
spark therapeutics
texas blog main
texas top stories
vertex pharmaceuticals
wisconsin blog main
wisconsin top stories
abeona therapeutics
accent therapeutics
achilles therapeutics
akcea therapeutics
akouos
alder biopharmaceuticals
What
patients
3
×
bio
drug
fda
roundup
advantages
ago
alnylam
approve
aren’t
awaits
bar
biological
brings
crossed
decades
decision
developers
discovered
drugs
expect
fingers
friday
gamble
gene
help
historic
imminent
long
market
medco’s
medicare
medicine
mover
moves
new
news
noteworthy
payers
physicians
Language
unset
Current search:
patients
×
" boston top stories "
×
" national blog main "
×
" alnylam pharmaceuticals "
×
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision